

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/653,717	09/01/2000	Gabriel Villafane	EGYP 3.0-008	5779	
530 7	2590 02/12/2003				
LERNER, DAVID, LITTENBERG,			EXAMINER		
KRUMHOLZ & MENTLIK 600 SOUTH AVENUE WEST			COOK, RE	COOK, REBECCA	
WESTFIELD, NJ 07090		ART UNIT	PAPER NUMBER		
			1614		

DATE MAILED: 02/12/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/653,717	VILLAFANE ET AL.				
7.447.667.y 7.161.67.	Examiner	Art Unit				
	Rebecca Cook	1614				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence address				
THE REPLY FILED 28 January 2003 FAILS TO PLACE Therefore, further action by the applicant is required to average final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this application application of the contraction of the contract of the cont	ation. A proper reply to a n places the application in				
PERIOD FOR RE	EPLY [check either a) or b)]					
 a)	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply be later than three months after the mail	g date of the final rejection. HE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension of the fee. The appropriate extension originally set in the final Office action; or	ion ion			
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a) 🖾 they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) ☐ they raise the issue of new matter (see Note b	elow);					
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the	е			
(d) they present additional claims without canceli	ng a corresponding number of fi	nally rejected claims.				
NOTE: See Continuation Sheet.						
3. Applicant's reply has overcome the following rejecti	on(s): <u>See Continuation Sheet</u> .					
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed amendment	t			
5.⊠ The a) affidavit, b) exhibit, or c) request for application in condition for allowance because: Sec		dered but does NOT place the				
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly				
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	• • •					
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: <u>none</u> .						
Claim(s) objected to:						
Claim(s) rejected: <u>10-16,18-28 and 30-49</u> .						
Claim(s) withdrawn from consideration:						
8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10. Other:		Rebecca Cook Primary Examiner Art Unit: 1614	,			

U.S. Patent and Trademark Office

Application No. 009/653,717

Continuation Sheet (PTO-303)

Continuation of 2: the recitation "at least 55% lower than the effective dose when L-DOPA is administered in the absence of said first component" in claim 15 raises new issues that require further search and consideration.

Continuation of 3: Applicant's reply has overcome the following rejection(s): in view of applicants' argument the rejection under 35 U.S.C. 112, paragraph two to "improving" is withdrawn.

Continuation of 5: Applicants argue the new limitation "L-DOPA in a dose at least 30% lower than the effective dose when L-DOPA is administered in the absence of the first component" is not suggested by Domino. However, this recitation is not recited in independent claims 15 and 28.